Skip to main content

Table 1 Correlation of EGFR and pEGFR expression with clinicopathological parameters, ER/PR, c-erbB-2, pAkt, uPAR, MMP-14 and VEGFR-1/Flt-1

From: Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas

Parameters

Total

EGFR

PEGFR

   

n (%)

P

n (%)

P

Menopausal status

Premenopausal

50

5 (10.0)

NS

13 (26.0)

NS

 

Postmenopausal

104

13 (12.5)

 

42 (40.4)

 

Histological type

Ductal

121

15 (12.4)

NS

41 (33.9)

NS

 

Lobular

32

3 (9.4)

 

13 (40.6)

 

Histological grade

1

23

1 (4.3)

NS

7 (30.4)

NS

 

2

90

11 (12.2)

 

35 (38.9)

 
 

3

36

6 (16.7)

 

11 (30.6)

 

Nuclear grade

1

53

1 (1.9)

0.001

18 (34.0)

NS

 

2

53

5 (9.4)

 

23 (43.4)

 
 

3

47

12 (25.5)

 

13 (27.7)

 

Tumour size

<2 cm

37

2 (5.4)

NS

13 (35.1)

NS

 

2 to 5 cm

91

11 (12.1)

 

32 (35.2)

 
 

>5 cm

25

5 (20.0)

 

9 (36.0)

 

Lymph node status

Noninfiltrated

61

6 (9.8)

NS

19 (31.1)

NS

 

Infiltrated

91

12 (13.2)

 

35 (38.5)

 

Stage

1

28

2 (7.1)

NS

9 (32.1)

NS

 

2

97

12 (12.4)

 

33 (34.0)

 
 

3

27

4 (14.8)

 

12 (44.4)

 

ER

Negative

70

14 (20.0)

0.005

20 (28.6)

NS

 

Positive

83

4 (4.8)

 

35 (42.2)

 

PR

Negative

78

13 (16.7)

NS

30 (38.5)

NS

 

Positive

75

5 (6.7)

 

25 (33.3)

 

c-erbB-2

Negative(<10)

60

5 (8.3)

NS

21 (35.0)

NS

 

Positive(≥ 10)

93

13 (14.0)

 

34 (36.6)

 

pAkt

Negative (<10)

49

3 (6.1)

NS

12 (24.5)

0.008

 

Positive (≥ 10)

72

11 (15.3)

 

35 (48.6)

 

uPAR

Negative (<15)

49

9 (18.3)

NS

12 (24.5)

0.049

 

Positive (≥ 15)

67

6 (9.0)

 

29 (43.3)

 

MMP-14

Negative (= 0)

93

13 (14.0)

NS

28 (30.1)

0.025

 

Positive (>0)

29

2 (6.9)

 

16 (55.2)

 

VEFGR-1/Flt-1

Negative (<30)

40

5 (12.5)

NS

9 (22.5)

0.016

 

Positive (≥ 30)

72

9 (12.5)

 

33 (45.8)

 
  1. EGFR, epidermal growth factor receptor; ER, oestrogen receptor; MMP, matrix metalloproteinase; NS, not significant; pAkt, phosphorylated Akt; pEGFR, phosphorylated epidermal growth factor receptor; PR, progesterone receptor; uPAR, urokinase plasminogen activator receptor; VEGFR, vascular endothelial growth factor receptor.